Bruker (NASDAQ:BRKR) Releases Earnings Results, Beats Estimates By $0.07 EPS

Bruker (NASDAQ:BRKR) posted its quarterly earnings data on Thursday. The medical research company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07, Briefing.com reports. The business had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. Bruker had a net margin of 14.41% and a return on equity of 29.94%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 earnings per share. Bruker updated its FY24 guidance to $2.79-2.84 EPS.

Bruker Trading Down 0.1 %

BRKR traded down $0.05 during trading on Friday, hitting $70.05. 1,959,840 shares of the company’s stock were exchanged, compared to its average volume of 860,901. The company has a current ratio of 1.80, a quick ratio of 0.99 and a debt-to-equity ratio of 0.83. Bruker has a 1 year low of $53.79 and a 1 year high of $94.86. The stock has a 50 day moving average price of $87.68 and a 200 day moving average price of $75.00. The firm has a market cap of $10.18 billion, a P/E ratio of 23.99, a price-to-earnings-growth ratio of 2.00 and a beta of 1.22.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were paid a dividend of $0.05 per share. The ex-dividend date was Thursday, February 29th. This represents a $0.20 annualized dividend and a yield of 0.29%. Bruker’s dividend payout ratio is currently 6.85%.

Insiders Place Their Bets

In other Bruker news, Director Hermann Fritz Requardt sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now directly owns 23,147 shares in the company, valued at $2,084,618.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 28.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Citigroup boosted their target price on shares of Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Stifel Nicolaus boosted their target price on shares of Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. The Goldman Sachs Group boosted their target price on shares of Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. upgraded shares of Bruker from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $60.00 to $90.00 in a report on Wednesday, February 14th. Finally, UBS Group boosted their target price on shares of Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $84.86.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.